V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005557 | 10003475 | 1.73 | 73.3 | Palliative (P) | 2017-06-14 | 2017-07-04 | Folfirinox | N | N | 10546337 | DACARBAZINE |
| 10005558 | 10003476 | 1.71 | 78.6 | Curative (C) | 2017-06-01 | 2017-06-01 | MITOMYCIN | N | N | 10547146 | RUXOLITINIB |
| 10005559 | 10003476 | 1.71 | 87.4 | Palliative (P) | 2017-09-16 | 2017-09-30 | Sunitinib | 02 | N | 10547146 | CHLORAMBUCIL + RITUXIMAB |
| 10005560 | 10003476 | null | 63 | Palliative (P) | 2018-12-19 | 2018-12-19 | Carbo F | N | N | 10547146 | CISPLATIN + VINORELBINE + RT |
| 10005561 | 10003476 | 1.74 | 85 | Palliative (P) | 2016-07-15 | 2016-08-20 | CVP R + ETOPOSIDE | N | N | 10547146 | CLADRIBINE |
| 10005562 | 10003477 | 0 | 0 | Neo-adjuvant (N) | 2019-04-03 | 2019-04-08 | TRASTUZUMAB | N | N | 10547997 | MITOMYCIN INTRAVESICULAR |
| 10005563 | 10003477 | 1.88 | 76.6 | Palliative (P) | 2017-04-21 | 2017-04-28 | Cladribine (subcut) 5 days | N | N | 10547997 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 10005564 | 10003477 | null | 77.85 | Curative (C) | null | 2014-06-12 | Brentuximab | 2 | null | 10547997 | RUXOLITINIB |
| 10005565 | 10003478 | 1.68 | 59.6 | Curative (C) | 2018-06-27 | 2018-07-06 | DOXORUBICIN | 2 | N | 10549203 | VISMODEGIB |
| 10005566 | 10003479 | 1.72 | null | Palliative (P) | 2018-12-28 | 2018-12-28 | CISPLATIN + FLUOROURACIL | 02 | N | 10550378 | ALEMTUZUMAB |
| 10005567 | 10003479 | null | 64.86 | Curative (C) | 2017-11-08 | 2017-11-14 | Ofatumumab Monthly | 02 | N | 10550378 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10005568 | 10003479 | 0 | null | Palliative (P) | 2016-02-26 | 2016-02-28 | Cetuximab +Cisplatin + FU (Cycle 1) | 2 | N | 10550378 | METHOTREXATE HIGH DOSE |
| 10005569 | 10003480 | 1.82 | 55.7 | Curative (C) | 2017-07-14 | 2017-07-14 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10551719 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005570 | 10003480 | 1.75 | 84.7 | Palliative (P) | 2017-12-11 | 2017-12-24 | Ipilimumab | N | N | 10551719 | IPILIMUMAB + NIVOLUMAB |
| 10005571 | 10008301 | 1.57 | 74.3 | Palliative (P) | 2018-01-04 | 2018-01-18 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10551906 | DOXORUBICIN |
| 10005572 | 10008301 | 1.69 | 92.1 | Palliative (P) | 2019-04-26 | 2019-05-08 | CARBOPLATIN + RT | N | N | 10551906 | CHLORAMBUCIL + RITUXIMAB |
| 10005573 | 10008301 | 1.79 | 76 | Palliative (P) | 2015-12-19 | 2016-01-14 | Pazopanib | 01 | Y | 10551906 | CISPLATIN + DOCETAXEL |
| 10005574 | 10003482 | 1.68 | 91.6 | Palliative (P) | 2019-01-01 | 2019-01-03 | UKALL14- Ph 2 Induction | N | Y | 10556445 | FCR |
| 10005575 | 10003483 | 0 | 67 | Palliative (P) | 2018-02-16 | 2018-02-21 | IPILIMUMAB + NIVOLUMAB | N | N | 10558042 | UKALL2014 |
| 10005576 | 10003483 | 1.63 | null | Curative (C) | 2019-03-04 | 2019-03-04 | MPV | 02 | N | 10558042 | BORTEZOMIB + THALIDOMIDE |
| 10005577 | 10003483 | 1.6 | 77.6 | Palliative (P) | 2019-06-30 | 2019-07-20 | RUXOLITINIB | 02 | N | 10558042 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005578 | 10003483 | 1.75 | 71.2 | Curative (C) | 2017-09-27 | 2017-10-11 | AML 18 Pilot Trial | null | N | 10558042 | SORAFENIB |
| 10005579 | 10003483 | 1.67 | 0 | Palliative (P) | 2018-05-09 | 2018-06-04 | Fluorouracil + Folinic + RT Bossett | N | N | 10558042 | ERLOTINIB |
| 10005580 | 10003483 | null | 98.3 | Disease modification (D) | 2018-10-22 | 2018-11-11 | Pazopanib | N | N | 10558042 | MELPHALAN |
| 10005581 | 10003483 | null | 74 | Palliative (P) | 2018-12-01 | 2018-12-27 | GEMCITABINE + NAB PACLITAXEL | Y | Y | 10558042 | CETUXIMAB + RT |
| 10005582 | 10003484 | 1.73 | 99 | Curative (C) | 2017-11-30 | 2017-12-05 | DA 3 + 10 | N | N | 10562316 | RCEOP |
| 10005583 | 10003485 | 1.77 | 103.7 | Curative (C) | 2015-05-19 | 2015-05-19 | CARBOPLATIN + RT | 02 | N | 10562649 | CETUXIMAB + RT |
| 10005584 | 10003485 | null | 55.7 | Palliative (P) | 2017-09-10 | 2017-09-29 | CARBO + DOCETAXEL + TRASTUZUMAB | N | null | 10562649 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005585 | 10003486 | null | 73 | Palliative (P) | 2018-11-08 | 2018-11-18 | CARBOPLATIN + PACLITAXEL + RT | N | null | 10127428 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 10005586 | 10003487 | 1.57 | null | Disease modification (D) | 2019-08-15 | 2019-08-20 | RUXOLITINIB | 2 | N | 10175757 | CAPECITABINE + CISPLATIN + RT |
| 10005587 | 10003488 | null | null | Neo-adjuvant (N) | 2018-06-11 | 2018-06-13 | IBRUTINIB | N | N | 10205908 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 10005588 | 10003488 | 0 | 60.8 | Adjuvant (A) | 2017-12-21 | 2017-12-26 | Cyclophosphamide + Docetaxel | N | N | 10205908 | PAZOPANIB |
| 10005589 | 10003489 | 0 | 75.7 | null | 2019-02-17 | 2019-02-24 | Lenalidomide 10mg (Cycle 1 to 25) | N | N | 10233873 | FLAIR TRIAL |
| 10005590 | 10003490 | 1.77 | 102 | null | 2018-08-31 | 2018-10-12 | AXITINIB | Y | N | 10273470 | DHAP - R |
| 10005591 | 10003490 | 1.52 | 60.9 | Palliative (P) | 2019-04-11 | 2019-04-12 | Vemurafenib | 01 | N | 10273470 | VEPEMB |
| 10005592 | 10003491 | 1.85 | 86 | Disease modification (D) | 2017-10-18 | 2017-10-18 | CAPECITABINE + CISPLATIN + EPIRUBICIN | N | N | 10287230 | PAZOPANIB |
| 10005593 | 10006899 | 1.56 | 72.5 | Curative (C) | 2017-07-24 | 2017-08-06 | Erlotinib | N | N | 10291740 | EC + PACLITAXEL |
| 10005594 | 10006899 | null | 70.41 | Curative (C) | 2019-07-19 | 2019-07-27 | IBRUTINIB | 02 | Y | 10291740 | VEMURAFENIB |
| 10005595 | 10003492 | 1.75 | 73 | Palliative (P) | 2017-07-03 | 2017-07-03 | MITOMYCIN | 2 | null | 10317444 | IPILIMUMAB + NIVOLUMAB |
| 10005596 | 10003492 | null | 67.8 | Curative (C) | 2019-05-09 | 2019-05-14 | BORTEZOMIB + THALIDOMIDE | N | N | 10317444 | CETUXIMAB + RT |
| 10005597 | 10003493 | 1.75 | 68 | Neo-adjuvant (N) | 2018-05-15 | 2018-05-21 | Cladribine (subcut) 5 days | N | N | 10330739 | MYELOMA XI TRIAL |
| 10005598 | 10003494 | 1.83 | 78.4 | Palliative (P) | 2018-02-19 | 2018-03-19 | CLARITY Trial | N | N | 10336508 | CLADRIBINE |
| 10005599 | 10003495 | 1.58 | 56.2 | null | 2016-06-15 | 2016-06-15 | DA | 2 | N | 10347342 | MPV |
| 10005600 | 10003496 | 1.77 | 89.5 | Curative (C) | 2018-11-19 | 2018-11-19 | Erlotinib | N | N | 10349419 | ECF |
| 10005601 | 10003496 | 1.65 | null | Curative (C) | 2017-09-28 | 2017-09-28 | ADD-ASPIRIN TRIAL | N | Y | 10349419 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005602 | 10008304 | 1.72 | 77 | Palliative (P) | 2019-07-13 | 2019-07-20 | R Chlorambucil | 02 | N | 10353954 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005603 | 10003497 | null | 77.6 | Palliative (P) | 2018-12-30 | 2019-01-05 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 02 | N | 10354338 | MIC |
| 10005604 | 10003498 | 1.81 | 98.4 | Curative (C) | 2015-03-11 | 2015-03-17 | Cetuximab + Radiotherapy Load | N | N | 10364117 | CETUXIMAB + RT |
| 10005605 | 10006902 | 1.76 | 81.9 | null | 2017-09-07 | 2017-09-07 | Bevacizumab 7.5mg/kg | N | N | 10386849 | GEMCITABINE + NAB-PACLITAXEL |
| 10005606 | 10006902 | 1.82 | null | Palliative (P) | 2016-11-22 | 2016-11-25 | Cape+Cisplatin+Trastuzumab Main | 2 | N | 10386849 | PREDNISOLONE + VINBLASTINE + RITUXIMAB |